Ignite Creation Date:
2025-12-25 @ 4:53 AM
Ignite Modification Date:
2026-01-04 @ 12:58 AM
Study NCT ID:
NCT04122118
Status:
COMPLETED
Last Update Posted:
2025-04-29
First Post:
2019-10-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor
Sponsor:
Thomas Jefferson University
Organization:
Study Overview
Official Title:
Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center
Status:
COMPLETED
Status Verified Date:
2025-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial studies how well pharmacist-led transitions of care works in the outpatient oncology infusion center for patients with solid tumor. Having a pharmacist in the outpatient oncology infusion center may help to identify and correct medical related problems and improve overall patient and staff satisfaction. Patients receiving education may benefit from gaining a better understanding of their antineoplastic therapy. Understanding the side effects associated with the therapy may also help patients better be prepared to manage any adverse effects they may experience.
Detailed Description:
PRIMARY OBJECTIVE:
I. To demonstrate the effectiveness of a clinical oncology pharmacist in the outpatient infusion center through education, and the identification and correction of medication related problem (MRP)s.
SECONDARY OBJECTIVE:
I. To evaluate overall patient and staff satisfaction with the added clinical oncology pharmacy education.
EXPLORATORY OBJECTIVE:
I. Estimate the cost avoidance utilizing the pharmacy services provided in the prospective trial.
OUTLINE:
PHASE I: Patients' medical records are reviewed.
PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider.
After completion of study, patients are followed up periodically.
I. To demonstrate the effectiveness of a clinical oncology pharmacist in the outpatient infusion center through education, and the identification and correction of medication related problem (MRP)s.
SECONDARY OBJECTIVE:
I. To evaluate overall patient and staff satisfaction with the added clinical oncology pharmacy education.
EXPLORATORY OBJECTIVE:
I. Estimate the cost avoidance utilizing the pharmacy services provided in the prospective trial.
OUTLINE:
PHASE I: Patients' medical records are reviewed.
PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider.
After completion of study, patients are followed up periodically.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| JT 13521 | OTHER | JeffTrial Number | View |